GSCAN
Desconocido
ColoMARK: Identification and development of novel colorectal cancer biomarkers via state of the art liquid bio...
GenomeScan B.V.
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2021-DN-01
The ColoMARK network integrates 17 teams with multidisciplinary expertise (omics, epidemiology, microbiome, circulating tumour DNA, bioinfor...
2022-07-06 - 2026-10-31 | Financiado
2022-07-06 - 2026-10-31 | Financiado
TrainCKDis: Multidisciplinary Training in Chronic Kidney Disease from genetic modifiers to drug discovery
GenomeScan B.V.
participó en un
H2020:
H2020-MSCA-ITN-2019
Chronic kidney disease (CKD) is recognized as an increasing global health problem. It currently affects 10-15% of the worldwide population,...
2019-08-12 - 2024-06-30 | Financiado
2019-08-12 - 2024-06-30 | Financiado
proEVLifeCycle: The life cycle of extracellular vesicles in prostate cancer from biogenesis and homing to function...
GenomeScan B.V.
participó en un
H2020:
H2020-MSCA-ITN-2019
The prostate cancer Extracellular Vesicle LifeCycle (proEVLifeCycle) network is an innovative, multidisciplinary training
program focused on...
2019-08-09 - 2023-09-30 | Financiado
2019-08-09 - 2023-09-30 | Financiado
ELBA: European Liquid Biopsies Academy Towards widespread clinical application of blood based diagnosti...
GenomeScan B.V.
participó en un
H2020:
H2020-MSCA-ITN-2017
Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensiti...
2017-08-30 - 2022-09-30 | Financiado
2017-08-30 - 2022-09-30 | Financiado
TransPot: Translational Research Network in Prostate Cancer
GenomeScan B.V.
participó en un
H2020:
H2020-MSCA-ITN-2016
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly...
2016-08-16 - 2021-04-30 | Financiado
2016-08-16 - 2021-04-30 | Financiado
RETHRIM: Restoring tissue regeneration in patients with visceral Graft versus Host Disease.
GenomeScan B.V.
participó en un
H2020:
H2020-PHC-2014-2015
Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or or...
2014-12-01 - 2021-12-31 | Financiado
2014-12-01 - 2021-12-31 | Financiado
HEALS: Health and Environment wide Associations based on Large population Surveys
GenomeScan B.V.
participó en un
FP7:
Assessing individual exposure to environmental stressors and predicting health outcomes implies that both environmental exposures and epi/ge...
Financiado
Financiado
OPTIBIOCAT: Optimized esterase biocatalysts for cost effective industrial production
GenomeScan B.V.
participó en un
FP7:
OPTIBIOCAT is a 48 months project aimed at developing biocatalysts based on feruloyl esterases (FAEs) and glucuronoyl esterases (GEs) for pr...
Financiado
Financiado
IMODE-CKD: Clinical and system omics for the identification of the MOlecular DEterminants of established Chron...
GenomeScan B.V.
participó en un
FP7:
IMODE-CKD integrates multi-disciplinary expertise in proteomics, metabolomics, transcriptomics, bioinformatics, pathology, and clinical scie...
Financiado
Financiado
SYSVASC: Systems Biology to Identify Molecular Targets for Vascular Disease Treatment
GenomeScan B.V.
participó en un
FP7:
Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowled...
Financiado
Financiado
EARLYNUTRITION: Long term effects of early nutrition on later health
GenomeScan B.V.
participó en un
FP7:
Nutrition during early development has an important impact on later health, particularly through greater obesity risk, as demonstrated by FP...
Financiado
Financiado
EPISTOP: Long term prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a ge...
GenomeScan B.V.
participó en un
FP7:
Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of...
Financiado
Financiado
INTREALL: International study for treatment of childhood relapsed ALL 2010 with standard therapy systematic i...
GenomeScan B.V.
participó en un
FP7:
Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood...
Financiado
Financiado
* No se disponen de datos de la empresa actual.